Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


IPO round-up: Lombard shelves US plans; Mainstay hopes for €23m

This article was originally published in Clinica

Executive Summary

Lombard Medical Technologies has postponed its plans for an initial public offering in the US, citing poor market conditions. The UK firm, which specialises in endovascular aneurysm repair (EVAR), had previously said it hoped to raise up to $80m, by filing on the Nasdaq market and delisting from London’s AIM stock exchange, on which it currently trades. It reduced this target slightly, saying in a filing with the US Securities and Exchange Commission (SEC) on 8 April that it anticipated selling just over 3.6 million shares at $15-18 each – giving it a maximum total of around $65m.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts